Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.5MCash on Hand
16.9mo Cash Runway
Follow TELO by emailGet an email when TELO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TELO, unsubscribe in one click. Privacy
📣 What TELO Says Is Next
in 2026 · “The Company is also preparing scientific manuscripts for publication submission and targeting abstract submissions and presentations at multiple oncology-focused scientific conferences in 2026.”
Company press release, Dec 17, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Financing Registers resale of 5,292,810 shares by selling securityholders, including 4,900,750 outstanding shares and 392,060 shares issuable on placement agent warrants. Company receives no proceeds from resales. Shares last closed at $0.88 on Nov 4, 2026. Form 424B3 · SEC filing
Oct 27, 2026 ·
Financing Registers for resale up to 5,292,810 shares of common stock held by selling securityholders, including 392,060 shares issuable on exercise of placement agent warrants. The shares were sold in an October 2026 private placement at $1.16 and $1.13 per share. The company will not receive proceeds from resales. Form S-3 · SEC filing
Oct 6, 2026 ·
Financing Telomir sold 4,843,300 common shares at $1.16 each in a private placement for about $5.6 million gross, including $1.0 million from existing shareholder John Paul DeJoria. Proceeds go mainly to the Telomir-Zn Phase 1/2 triple-negative breast cancer trial. Form 8-K · SEC filing · Press release
Sep 17, 2026 ·
Clinical trial Telomir announced a peer-reviewed preclinical study in International Journal of Molecular Sciences showing Telomir-Zn improved visual function and restored retinal structure in an AMD model. The company's clinical priority remains a Phase 1/2 trial in triple-negative breast cancer. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Shareholder vote Telomir shareholders re-elected four directors, ratified Salberg & Company, P.A. as auditor for fiscal 2026, and approved adjourning the meeting if needed. About 68.53% of outstanding shares were represented at the September 11, 2026 annual meeting. Form 8-K · SEC filing
Sep 14, 2026 ·
Clinical trial Telomir announced Ohio State University preclinical data showing Telomir-Zn inhibited cell growth in human (HOS) and canine (D17, Abrams) osteosarcoma cell lines at similar low drug concentrations. The company is discussing a possible canine in vivo study while its TNBC program advances toward site initiation. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1/2 · Upcoming Trial · Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TELO holds $4.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $799,386/quarter from operations,
an estimated runway of 16.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:68 · High
Cash runway 17 months +18
ATM program on file since Feb 2025 +15
Shelf registration (S-3, Feb 2025) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report.10-Q, Nov 2026
Share count +114% in a year +20
Raised after last reported balance sheet (Oct 2026) -10
Share count 73,675,706 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TELO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TELO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.